Aavantibio

Developer of gene transfer therapies for neuromuscular disease

placeGainesville, Florida, United States calendar_todayFounded 2017 groups57 employees language aavantibio.com

Innovation

8 patent families — focus: Human necessities, Chemistry & metallurgy, Physics & computing; filing pace accelerating. Cited 75 times.

YearFilings
20221
20237
20247
20258
20264

Investor mix

6 investors on record; lead investors include Muscular Dystrophy Association, GoFar, Perceptive Advisors, Bain Capital.

Investor typeCountShare
Venture capital117%
Private equity117%
Other / undisclosed467%
Coming soon